A number of compounds related to rifampin which act as expected in the Escherichia coli system have been tested for their ability to inhibit the vaccinia particle deoxyribonucleic acid-dependent ribonucleic acid (RNA) polymerase in vitro.
Rifamycin and its semisynthetic derivatives are antibiotics which are known to be active against many bacteria. The molecular mechanism of this activity has been studied and is largely understood. Many of the rifamycins, including rifampin, are known to bind firmly and specifically at low concentrations to the bacterial deoxyribonucleic acid (DNA)-dependent ribonucleic acid (RNA) polymerase, preventing the initiation of RNA synthesis (5, 25, and 30) . One rifamycin derivative, rifampin, has been found specifically to inhibit the growth of vaccinia virus at a late stage, but extensive studies on the nature of this inhibitory action of high concentrations of rifampin have failed to demonstrate that the mechanism of its antiviral action is similar to its antibacterial action (9, 18, 19, 27) . The synthesis of viral RNA, DNA, and early and late proteins, though quantitatively affected, is not prevented by inhibitory concentrations of the drug (1, 15 17, 26) , and the activity of the virion-associated DNA-dependent RNA polymerase is only slightly inhibited at high concentrations of rifampin (3, 15, 18, 26) . Moreover, the virion-associated RNA polymerase of rifampin-resistant mutants of vaccinia virus is inhibited to the same degree as that of wild-type virus by these concentrations of the drug (26) .
In this paper we report the effects of several rifamycins and related antibiotics on the activity of the virion-associated DNA-dependent RNA polymerase of vaccinia virus.
MATERIALS AND METHODS Virus. Vaccinia virus (Evans vaccine strain) and rifampin-resistant mutants of vaccinia virus were grown in BHK-21 C13 cells and purified by the method of Joklik (10) .
The isolation of rifampin-resistant mutants of vaccinia virus has been described previously (27) .
Bacteria. Escherichia coli strain 162 cells were obtained from the Microbial Research Establishment, Porton, Wilts. The E. coli 162 rifampin-resistant (RifR) strain was isolated as a single colony after incubation of nutrient agar plates containing 500 jg of rifampin per ml seeded with 109 cells of E. coli 162. Antibiotics. The semisynthetic rifamycin derivatives studied were ( Fig. 1) rifamycin SV, 3-formyl rifamycin SV, compounds 39 and 18, rifampin, N-demethylrifampin, and AF/ABDP, which only differ in the side chain attached to the three position on the naphthohydroquinone moiety of the molecule (16, 24) , and DDE and rifarubin S, which both possess a modified aliphatic bridge (32) . Also studied were tolypomycin R (12) and a streptovaricin complex (23) , which are naturally occurring antibiotics with many structural similarities to the rifamycins (Fig. 1) EFFECT OF ANTIBIOTICS ON POLYMERASE 162 RifR (both containing 6.6 mg of protein/ml) were prepared, the bacterial DNA was removed, and DNA-dependent RNA polymerase activity was assayed by using the method of Chamberlin and Berg (2) with minor modifications. The cell-free extract contained 10 mM Tris-hydrochloride buffer (pH 7.9), 1 mM MgCl2, 0.1 mM ethylenediaminetetraacetic acid (EDTA), and 50 mm sodium benzoate. The DNA in the cell-free extract was precipitated by dropwise addition of 10% streptomycin sulfate with stirring until the final concentration was 0.5%. After standing for 10 min, the precipitate was removed by centrifugation (30,000 X g for 15 min.). The final assay mixture (0.25 ml) contained cell-free extract (0.1 ml), 15 In experiments in which the effect of the addition of 3-formyl rifamycin SV, AF/ABDP, DDE, or actinomycin D after the beginning of RNA synthesis was examined, a virus suspension containing 2.6 X 1010 particles/ml was pretreated with Triton-X-100 and 2-mercaptoethanol as described above. The final assay mixture (0.35 ml) contained 0.1 ml of pretreated virus suspension, MgCl2 (5.7 8.5) . This was incubated with shaking for 15 min at 37 C, 20-,uliter samples being taken at 5-min intervals. The rest of the assay mixture (0.25 ml) was then cooled to 0 C, and 0.065 ml of solution containing antibiotic (1 mg/ml) was added; the final concentration of antibiotic was 206 ,ug/ml. Samples were taken and incubation with shaking at 37 C was resumed.
RESULTS
Effect of antibiotics on growth and on DNAdependent RNA polymerase of E. coli. All of the antibiotics examined in this study inhibited the growth of E. coli 162 with the exception of DDE and rifarubin S ( Fig. 2A) . Rifampin, 3-formyl rifamycin SV, compound 18, and compound 39 strongly inhibited the growth of E. coli, whereas only slight inhibition was observed with AF/ ABDP and streptovaricin. The intensity of inhibition by tolypomycin R varied from experiment to experiment, indicating that the compound is unstable. A rifampin-resistant mutant of E. coli 162, which was able to grow in the presence of 500 ,g of rifampin per ml, was isolated. Growthinhibition tests showed that the mutant had simultaneously acquired resistance to the inhibitory effects of the other rifamycins and related compounds (Fig. 2B) .
The effect of some of the antibiotics on the DNA-dependent RNA polymerase was tested at a concentration of 200 ,ug/ml by using cell free extracts of wild-type and rifampin-resistant E. coli. The DNA from the cell-free extract was removed by precipitation with streptomycin sulfate to make the enzyme activity dependent on added template. The enzyme activity of the wild-type E. coli was completely inhibited even by those antibiotics, like AF/ABDP, which had only moderate effects on the growth of E. coli ( Table  1 ). The only exception was DDE which only partially inhibited enzyme activity even at this high concentration. These results confirm the findings of Wehrli and Staehelin (32) , who found that many rifamycin derivatives inhibited enzyme activity in vitro equally well despite differences in effectiveness in vivo, whereas DDE and rifarubin S did not inhibit enzyme activity. They found good correlation between the effectiveness of these compounds and their ability to form a stable complex with the enzyme. The enzyme of the rifampin-resistant mutant was partially resistant to all of the antibiotics tested ( Table 1 ), confirming that the mutation had altered the RNA polymerase. It is of interest that the enzyme VOL. 8, 1971 SZILAGYI of the rifampin-resistant mutant was more resistant to AF/ABDP than rifampin itself.
Effect of antibiotics on virion-associated DNAdependent RNA polymerase of vaccinia virus. The activity of virion-associated DNA-dependent RNA polymerase was assayed after treatment of the virus with Triton-X-100 and 2-mercaptoethanol. Preliminary testing of the compounds showed that at a concentration of 200 jig/ml, 3 -formyl rifamycin SV, AF/ABDP, or DDE exerted a profound inhibitory effect on enzyme activity, comparable to that produced by actinomycin D or Congo red (13) at the same concentration (Fig. 3) . Compound 18, compound 39, and tolypomycin R at 200 ,ug/ml produced partial inhibition, whereas at this concentration rifamycin SV, rifampin, N-demethylrifampin, streptovaricin, and rifarubin S exerted little effect (Fig. 3, 4) . (As rifarubin S was difficult to dissolve, its effective concentration in the reaction mixture was probably lower than 200 Ag/ml.)
The effects of the compounds which produced partial inhibition were then examined at a concentration of 500 jsg/ml (Fig. 4, 5 ). Increased inhibitory activity was found with rifampin compound 39 and tolypomycin R and compound 18 , which blocked enzyme activity completely at this concentration. The most active compounds were then reinvestigated at concentrations lower than 200 ug/ml; greater than 90% inhibition of enzyme activity occurred in the presence of 150 ,ug of AF/ABDP, DDE, and 3-formyl rifamycin SV per ml (Fig. 6 ). However, with lower concentrations of these antibiotics (10 to 30 gg/ml), enhanced enzyme activity was observed.
ABDP, the side chain of AF/ABDP, was also tested and was found to have no detectable effect at a concentration of 500 ;kg/ml (Fig. 5 ).
Compounds which inhibited or partially inhibited the enzyme activity exerted their effect from the start of the enzyme assay, with the exception of tolypomycin R, which at concentrations of 200 and 500 jug/ml had hibited the enzyme activity ( Fig. 3-5 After the commencement of RNA synthesis by detergent-treated virus in the in vitro system, the addition of inhibitory concentrations of 3-formyl rifamycin SV, AF/ABDP, or DDE halted further RNA synthesis without apparent delay (Fig. 7) although a small delay in inhibition masked by the degradation of RNA cannot be ruled out. A similar effect was observed after the addition of actinomycin D. It is of interest that AF/ABDP, unlike the other compounds, not only immediately stops the reaction but also prevents any breakdown or loss of the reaction product.
Effect of antibiotics on virion-associated DNAdependent RNA polymerase of rifampin-resistant mutants of vaccinia virus. The effect of the rifamycins and related antibiotics was tested on the virion-associated DNA-dependent RNA polymerase of two rifampin-resistant mutants of vaccinia virus which had been independently isolated from the Evans strain. The properties of mutant VH have been described previously (27) ; in the presence of 100 ,ug of rifampin per ml, the plating efficiencies in BHK-21 C13 cell monolayers of mutant VH and mutant S were 27 and 26%, respectively, whereas that of wild-type vaccinia virus was less than 0.01%. Results of in vitro enzyme assays showed that the antibiotics inhibited the DNA-dependent RNA polymerase of both rifampin-resistant vaccinia virus strains to the same extent as the enzyme of the rifampinsensitive wild-type virus (Table 3) .
DISCUSSION
Experiments with several rifamycin derivatives and related antibiotics show that 3-formyl rifamycin SV, AF/ABDP, and DDE inhibit vaccinia particle DNA-dependent RNA polymerase in an in vitro system at concentrations of 150 ,ug/ml. Partial inhibition was achieved with compound 18, compound 39, and tolypomycin R at 200 ,ug/ml; of these, only compound 18 completely inhibited enzyme activity when the concentration was raised to 500 ,g/ml. When tested at 200 ,g/ml, rifamycin SV, rifampin, N-demethylrifampin, rifarubin S, and streptovaricin showed little effect on in vitro RNA synthesis. These findings are in good agreement with earlier observations, where only slight inhibition was noted by rifampin (27) and by streptovaricin (21) .
The effect of these antibiotics at high concentration on the growth of E. coli was also tested. Rifampin, 3-formyl rifamycin SV, compound 39, compound 18, and tolypomycin R strongly inhibited bacterial growth. Only moderate inhibition of growth was achieved with AF/ABDP and streptovaricin, whereas DDE and rifarubin S had no effect at all. The resistance of a rifampinresistant mutant to all of these antibiotics confirmed that the mode of action of these antibiotics is identical in E. coli; that is, they act directly on the DNA-dependent RNA polymerase enzyme (6, 8, 29) . This was further confirmed in a cellfree system; the in vitro RNA synthesis by the enzyme of the rifampin-resistant mutant was only partially inhibited even by high concentrations of these antibiotics which were effective against the wild type of enzyme. The differences in the effectiveness of inhibition of bacterial growth by these antibiotics was also shown by the in vitro enzyme system to be due probably to differences in permeability of the bacterial envelope. An exception was DDE which had little effect on the enzyme. These differences are in agreement with the findings of Werhli and Staehelin (32), who found good correlation between the complex-forming ability of many rifamycin derivatives and their inhibitory effect on the E. coli RNA polymerase.
Comparison of the relative effectiveness of the antibiotics in the bacterial and viral systems reveals striking differences. For example, whereas DDE does not complex with or inhibit bacterial enzyme (32) , it strongly inhibits the activity of the vaccinia virus particle enzyme. On the other hand, other compounds, such as rifampin, rifamycin SV, etc., are very potent inhibitors of the E. coli enzyme; even at very high concentrations (500 Ag/ml), they only moderately inhibit the activity of the vaccinia virus enzyme. Of the compounds we tested, only 3-formyl rifamycin SV seems to be a good inhibitor of both enzyme activities. Another point to note is that the inhibition of viral enzyme by even the most active inhibitors of viral RNA synthesis such as AF/ ABDP or DDE required a more than 100-fold greater concentration of inhibitor than the concentration of rifampin needed to inhibit the bacterial enzyme. For example, rifampin inhibits the E. coli enzyme by more than 90% at 0.6 gg/ml in an in vitro system (32) . We have observed other differences between the characteristics of inhibition by AF/ABDP, DDE, and 3-formyl rifamycin SV in the viral system and the characteristics of inhibition by rifampin in the E. coil system. First, the inhibition of the activity of the virus enzyme by these compounds is at least partially reversible, whereas the strong binding of rifampin to the bacterial enzyme results in irreversible inhibition (30) . A second striking difference is that addition of any of the three antibiotics after the commencement of viral RNA synthesis halted further synthesis without apparent delay, whereas in the bacterial system RNA synthesis continues until the polymerase reaches the next site of RNA initiation (25) .
Recently, Gurgo et al. (7) reported that some rifamycin derivatives, including AF/ABDP and N-demethylrifampin, inhibit the RNA-dependent DNA polymerase of several RNA tumor viruses.
Comparing their results with ours, it appears that AF/ABDP is inhibitory in both enzyme systems, and N-demethylrifampin only inhibits in the RNA tumor virus system. The observed differences in the effectiveness of the antibiotics in the bacterial system, the vaccinia system, and in the RNA tumor virus system of Gurgo need comment. We believe that the range of effectiveness indicates that the antibiotics interact directly with proteins and that these are the polymerases themselves. This is known to be the case in E. coli and so far there is no evidence to suppose that it is not so in the two other enzyme systems. The differences in the effectiveness of different rifamycins can be postulated to depend on differences between the enzyme molecules in the different systems. Possibilities such as the binding of inhibitor with the template in a similar fashion to actinomycin D are unlikely, because the compound DDE, which is active in the vaccinia virus system, should then be active in the E. coli system as well. The possibility that the action of the compounds is directed against some of the substrates is also unlikely as their action on RNA synthesis by the E. coli enzyme and the vaccinia virus enzyme should again be similar. Elucidation of the exact mode of action 139 VOL. 8, 1971 on November 12, 2017 by guest http://jvi.asm.org/ Downloaded from SZILAGYI AND PENNINGTON of these antibiotics in the vaccinia virus system has to wait until the enzyme is purified at least to such an extent that it requires exogenous DNA template. Every attempt to achieve this aim so far has failed. The possibility that the protein on which the rifamycins act in the vaccinia virus system is not the polymerase molecule itself, but is a protein related to the RNA-synthesizing system in some way, cannot therefore be ruled out. The kinetics of inhibition by tolypomycin R suggests the possibility that the mode of inhibition by this compound is different from that of rifamycin antibiotics.
We chose rifamycin derivatives with widely different chemical compositions in an attempt to elucidate the structural requirements for inhibition of the vaccinia RNA polymerase activity. Rifamycins consist of a napthohydroquinone ring which is spanned by a long aliphatic bridge. Many semisynthetic derivatives of rifamycin have compounds of various complexity added to the carbon atom 3 of the ring or have a modified aliphatic bridge. The simplest compound, rifamycin SV, inhibited the virus enzyme activity slightly. However, when the aliphatic bridge was shortened by epoxidation, the compound DDE became a very strong inhibitor. This suggests that the stereochemistry of the aliphatic bridge is important. This same change in configuration leads to loss of activity in the bacterial system (32) . The importance of the aliphatic bridge is further substantiated by the fact that the cleavage of the epoxidated bridge (rifarubin S) results in loss of activity in both systems. Substitutions in the carbon 3 position on the napthohydroquinone ring give compounds with varying activity in the viral system. We were unable to find any correlation between the chemical composition of these side chains and the potency of inhibition. However, in the viral systems inhibitory activity resides in the entire molecule since the side chain of AF/ABDP alone is not inhibitory, even at very high concentrations. It is possible that the activity depends on an effect of the side chain on the stereochemistry of the aliphatic bridge, a suggestion forwarded by Wehrli and Staehelin (32) , for the bacterial system. It would be interesting to see whether a rifamycin derivative containing both epoxydated aliphatic bridge and a side chain (like in 3-formyl rifamycin SV or AF/ABDP) would have enhanced effectiveness.
Since the DNA-dependent RNA polymerase of rifampin-resistant mutants of vaccinia virus is inhibited to the same extent as wild-type virus, it appears to be unlikely that rifampin inhibits virus development in vivo by blocking the virion RNA polymerase activity. This is in agreement with the finding that viral RNA, protein, and DNA synthesis, although affected, is not inhibited by concentrations of rifampin which inhibit virus development. Further evidence that the inhibition of enzyme activity is unlikely to be responsible for the specific antiviral effect of rifampin has been obtained by Pennington and Follett (20) . By using the same inhibitors as in the experiments reported here, they showed that, when many of the compounds were substituted for rifampin late in the virus-growth cycle, the block in virus development produced by rifampin was maintained. However, the amounts required to maintain the arrest in virus development did not correspond with the amounts required to inhibit the viral enzyme. For example, AF/'ABDP produces a profound inhibition of virus RNA polymerase at 100 Ag/'ml but only partially maintains the block in virus maturation at 1, 000 ,gg/ml. Conversely, 100 jig of compound 18 per ml completely maintains the block of virus maturation, a concentration much less than that required to produce a complete enzyme block. 
